AppMatic Tech builds AI document intelligence systems for regulated industries, using Python, LLM orchestration, retrieval pipelines, and audit-logged access control for healthcare and life sciences document workflows. AppMatic Tech is based in Ahmedabad, India, has shipped 330+ products since 2017, and built Anvahi, a HIPAA-compliant clinical documentation platform.
Most coverage of AI in pharma is about marketing. Personalised HCP engagement, content generation at scale, next-best-action targeting. That is where the conference talks are. It is not where the measurable return is. The clearest AI returns in pharma right now sit in regulatory operations, in the unglamorous work of compiling submissions, screening promotional copy, and releasing batches. These processes share a profile that makes them unusually well suited to automation: they are high-volume, high-stakes, and rule-bound, and they already have a baseline measured in hours and headcount, which means the saving is provable rather than asserted.
Key takeaways
AI in pharma regulatory workflows moved from pilot to standard practice during 2025 and 2026, with human oversight as the fixed constraint rather than an optional safeguard.
| Point | Detail |
|---|---|
| Regulatory ops beats marketing on provable ROI | Submission compilation, MLR review, and batch release have existing baselines in hours and headcount. Brand-side AI spend rarely has a comparable before-and-after number. |
| Regulators have set a direction, not a ban | The FDA's January 2025 draft guidance proposes a risk-based credibility framework tied to a defined context of use, not a prohibition. |
| FDA and EMA are now aligned | Ten joint Guiding Principles of Good AI Practice in Drug Development were published on 14 January 2026, covering research through post-market safety monitoring. |
| Human sign-off is non-negotiable | Every current regulatory position keeps a human accountable for approval. AI belongs in the pre-screening layer, not the decision layer. |
| Apply AI to the rule-checking layer | The pattern that works in regulated industries targets rule-checking and cross-referencing, not creative generation. |
| Reported gains vary widely | Published figures range from 30% faster submission publishing to 75% shorter MLR cycles. Treat vendor-reported ranges as directional and measure your own baseline first. |
Why is regulatory operations the highest-ROI AI use case in pharma?
The pattern that holds across every regulated industry is that the highest-value AI implementations take a process that is high-stakes, high-volume, and rule-bound, and apply AI to the rule-checking layer rather than the creative layer.
Regulatory operations fits that profile precisely. A Common Technical Document submission is not a creative artefact. It is a structured dossier assembled against a published specification, where most of the labour is cross-referencing, consistency checking, and format validation. Those are exactly the tasks where a model that is merely reliable outperforms a human who is expensive, scarce, and prone to fatigue across thousands of pages.
Marketing AI struggles to prove the same case. The output is judged on persuasion, the baseline is contested, and the counterfactual is unknowable. Regulatory operations has none of those problems. A medical writer's hours on a submission are already tracked. A batch release already has a cycle time. The saving is arithmetic, not attribution.
Pro tip: Before scoping any AI project in a regulated workflow, confirm the baseline is already instrumented. If nobody can tell you the current hours per submission or the current MLR cycle time, the first deliverable is measurement, not a model. Projects that skip this step cannot defend their own business case at the first review.
What have the FDA and EMA actually said about AI in drug development?
Two regulatory events define the current position, and the second is the more important one.
In January 2025 the FDA issued its first draft guidance on the subject, Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products. Rather than restricting AI, it proposes a risk-based credibility assessment framework: sponsors define a specific context of use for a model, assess the risk attached to that use, and compile credibility evidence proportionate to that risk. The FDA noted it had already seen more than 500 drug and biological product submissions containing AI components since 2016, so the guidance formalised existing practice rather than opening a new door. The comment period closed in April 2025.
One scope detail is routinely misread and matters commercially. The guidance addresses AI used to produce information or data supporting regulatory decisions about safety, effectiveness, or quality. It does not extend to drug discovery, or to operational efficiencies that do not affect patient safety, product quality, or study reliability. A system that compiles and cross-checks a dossier for internal efficiency, without generating the underlying evidence, may therefore sit outside the guidance's scope entirely. That is a question for regulatory counsel on a specific implementation, not an assumption to build on.
The more significant 2026 development is international alignment. On 14 January 2026 the FDA and EMA jointly published ten Guiding Principles of Good AI Practice in Drug Development, spanning early research, clinical trials, manufacturing, and post-market safety monitoring, and applying to both human and veterinary medicines. The principles emphasise ethical and human-centric values, a risk-based approach, a clearly defined context of use, data governance, multidisciplinary expertise, lifecycle management, transparency, and human oversight. They are not binding guidance, but both agencies have signalled that they will underpin future rulemaking in each jurisdiction, and EU guideline development is already underway.
The direction is unambiguous. AI in pharma regulatory workflows is moving from pilot to standard practice, with human oversight fixed as the constraint.
How does AI-assisted CTD and eCTD compilation actually work?
The Common Technical Document is the submission backbone for FDA, EMA, and ICH approvals. Compiling one manually for a single NDA or IND consumes a large volume of regulatory affairs and medical writing time, most of it spent on work that is mechanical rather than judgement-based.
An AI-assisted pipeline typically handles a defined set of tasks:
- Auto-populating Module 2 summaries from source data already present in Modules 3 through 5, rather than having a writer re-key it.
- Cross-referencing clinical study reports against the CTD structure to confirm every required element is present and correctly placed.
- Flagging internal inconsistencies where the same figure appears differently across documents, which is a common and expensive late-stage finding.
- Classifying documents into the correct eCTD modules automatically.
- Validating hyperlinks, bookmarks, and metadata across thousands of PDF pages, a task where exhaustive machine checking clearly beats sampling.
- Pre-screening for compliance gaps before a human reviewer opens the dossier.
Published results vary considerably and should be read with care. One reported case describes a top-10 pharmaceutical company reducing submission publishing time by 30% after adopting AI-assisted regulatory publishing. Structured content reuse is reported to cut authoring time by up to 50%. Higher figures circulate, including claims of very large reductions in first-draft time, but these typically measure a narrow drafting sub-task rather than the end-to-end cycle, and most originate from vendors rather than independent study.
The defensible position is that the mechanical layer of submission assembly compresses substantially, that the review and judgement layer does not, and that any specific number should come from your own instrumented baseline rather than a case study of somebody else's process.
Pro tip: Scope the first build against the cross-referencing and consistency-checking layer, not draft generation. Consistency defects are objectively verifiable, so the system can be tested against a known-good historical submission. Draft quality is subjective, which makes acceptance criteria hard to write and disputes hard to settle.
What does AI change about MLR review for pharma marketing?
Marketing does have a genuine AI use case, but it is on the compliance side rather than the creative side.
Medical-legal-regulatory review is a known bottleneck. Reported cycle times at mid-sized and large pharmaceutical companies stretch to 50 or 60 days per content item in the worst cases, against an industry benchmark closer to 21 days, with pieces cycling back repeatedly over defects that are mechanical rather than substantive.
The workable pattern is pre-screening. Before a human compliance officer reviews new promotional material, natural language models scan for missing safety statements, off-label claims, unsupported efficacy language, and claims whose cited reference does not actually support them. Reference verification in particular is exhaustive, mechanical work that humans do poorly at volume and machines do well.
This compresses the review cycle without removing human sign-off, which is the only model regulators currently accept. Veeva has reported up to a 75% reduction in MLR cycle time with AI-supported review. As with submission figures, treat that as directional and vendor-reported.
The distinction that matters: AI is removing the rework loop caused by mechanical defects, not the review itself.
What does a batch release workflow actually save?
Batch release is the clearest example of a rule-bound, high-volume workflow where the arithmetic is simple enough to check.
Consider a site producing 500 batch releases annually, where an AI-assisted digital release saves one working day of QA time per batch:
| Input | Value |
|---|---|
| Batch releases per year | 500 |
| QA time saved per release | 1 working day |
| Fully loaded QA cost per day | $1,000 (approximately $250,000 annually over 250 working days) |
| Indicative annual saving | $500,000 |
This is illustrative arithmetic, not a case study or a published finding. The figure is entirely determined by the three assumptions above, and it moves proportionally with each of them. A site releasing 150 batches, or saving four hours rather than a full day, or operating at a lower loaded cost, produces a materially smaller number.
The reason to run the calculation anyway is that it establishes whether the workflow is worth instrumenting at all. If the honest version of the arithmetic lands below the cost of the build, that is a useful answer arrived at cheaply.
Where does AI fit across pharma workflows?
Not every pharma workflow suits automation equally. The table below maps the main candidates against the properties that actually predict success.
| Workflow | Rule-bound? | Volume | Human sign-off required | AI fit |
|---|---|---|---|---|
| CTD and eCTD compilation | High | High | Yes, at approval | Strong |
| MLR pre-screening | High | High | Yes, always | Strong |
| Batch release review | High | High | Yes, QP release | Strong |
| Pharmacovigilance case intake | High | Very high | Yes, at assessment | Strong |
| Clinical study report drafting | Medium | Medium | Yes | Moderate |
| Protocol design | Low | Low | Yes | Weak |
| HCP marketing personalisation | Low | High | No | Weak on provable ROI |
| Drug discovery target selection | Low | Low | Not applicable | Outside this article's scope |
The pattern is consistent. The stronger the rule structure and the higher the volume, the better the fit, and the more defensible the business case.
What AppMatic Tech builds, and what it does not
Being direct about scope matters more in this sector than in most.
AppMatic Tech does not have FDA or EMA regulatory submission expertise and does not claim it. Any CTD or eCTD system requires regulatory affairs ownership inside the pharmaceutical organisation, plus qualified regulatory counsel. Nothing in this article substitutes for either. Validation under GxP, and the credibility evidence the FDA framework expects, are the sponsor's responsibility.
What AppMatic Tech builds is the engineering layer underneath those workflows: document intelligence pipelines that parse and cross-reference structured and unstructured source documents, retrieval architecture that grounds model output in the organisation's own data rather than model memory, audit logging on every data access, and role-based access control designed in from the architecture phase rather than retrofitted.
That work is closest in shape to Anvahi, a HIPAA-compliant clinical documentation platform AppMatic Tech built that generates structured clinical notes in practitioner-specific formats from recorded consultations. The engineering problem, turning unstructured source material into a structured, auditable document that a qualified human then signs off, is the same problem regulatory document intelligence presents. The regulatory overlay is not.
The full build is documented in the Anvahi case study. For the architecture patterns behind grounding model output in live organisational data, see RAG implementation in production and lessons from LLM integration in production. For the compliance-ready engineering foundation in a healthcare context, see building healthcare apps for the Saudi market and the healthcare app development service page.
Contact AppMatic Tech at contact@appmatictech.com to scope a document intelligence build.
Sources
| Claim used in this article | Source |
|---|---|
| FDA and EMA published ten joint Guiding Principles of Good AI Practice in Drug Development on 14 January 2026 | EMA, EMA and FDA set common principles for AI in medicine development |
| Full text of the ten guiding principles | EMA, Guiding Principles of Good AI Practice in Drug Development (PDF, January 2026) |
| FDA draft guidance, risk-based credibility framework, and 500+ submissions with AI components since 2016 | FDA, Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products, draft guidance, January 2025. Summarised by RAPS |
| MLR cycle times of 50 to 60 days against a ~21 day benchmark, and AI pre-screening patterns | pharmaphorum, Accelerating the medical, legal and regulatory review leveraging AI |
| 30% reduction in submission publishing time; up to 50% authoring time reduction via structured content reuse; up to 75% MLR cycle reduction | Vendor-reported figures collated by IntuitionLabs, Agentic AI for pharma regulatory document automation. Directional only, not independently verified |
| $500,000 annual batch release saving | Not a source. Illustrative arithmetic from the three assumptions stated in that section |
The FDA's own guidance pages could not be linked directly because fda.gov blocks automated retrieval. The guidance is findable by its full title above through the FDA guidance document search.
Frequently Asked Questions
- Where is AI delivering the clearest ROI in pharma in 2026?
- Regulatory operations rather than marketing. The highest-value implementations apply AI to processes that are high-volume, high-stakes, and rule-bound: Common Technical Document compilation, medical-legal-regulatory pre-screening of promotional material, and batch release review. These workflows have measurable baselines in hours and headcount, which makes the saving provable in a way brand-side AI spend rarely is.
- Does the FDA allow AI in drug submissions?
- Yes, within a risk-based framework. The FDA's draft guidance 'Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products', issued January 2025, proposes a risk-based credibility assessment framework tied to a defined context of use rather than prohibiting AI. The FDA has reported experience with more than 500 drug and biological product submissions containing AI components since 2016.
- What did the FDA and EMA agree about AI in January 2026?
- On 14 January 2026 the FDA and EMA jointly published ten Guiding Principles of Good AI Practice in Drug Development. The principles span early research, clinical trials, manufacturing, and post-market safety monitoring, and apply to human and veterinary medicines. They emphasise human oversight, a risk-based approach, defined context of use, data governance, lifecycle management, and transparency.
- Can AI replace the human reviewer in MLR or regulatory sign-off?
- No. Every current regulatory position, including the joint FDA and EMA principles, treats human oversight as non-negotiable. The workable pattern is AI as a pre-screening layer that catches missing safety statements, unreferenced claims, and formatting failures before a human compliance officer opens the file, compressing the review cycle without removing human accountability for approval.
- Has AppMatic Tech built FDA or EMA regulatory submission systems?
- No. AppMatic Tech does not claim regulatory submission or pharmaceutical compliance expertise, and any CTD or eCTD system requires in-house regulatory affairs ownership plus qualified regulatory counsel. What AppMatic Tech builds is the engineering layer underneath: document intelligence pipelines, retrieval and cross-referencing systems, audit logging, and role-based access control, including Anvahi, a HIPAA-compliant clinical documentation platform.